Login to Your Account

A Fat Opportunity

Autoimmune Drug Candidate Helps Mice Keep Trim Waists

By Anette Breindl
Science Editor

Wednesday, May 29, 2013
A peptide based on sea anemone venom, already in early clinical trials for autoimmune diseases, also shows promise in the metabolic arena, scientists reported this week. ShK-186 is a peptide that blocks a potassium channel, Kv1.3. The use of a channel blocker for metabolic indications is unusual; often, metabolic drugs target hormones or their receptors.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription